Coya Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $-21.2M | $-14.9M | $-8.0M | $-12.2M | $-4.9M |
| Depreciation & Amortization | — | — | — | — | — |
| Depreciation | $27.4K | $27.4K | $27.4K | $27.4K | $16.1K |
| Amortization | — | — | — | — | — |
| Stock-Based Compensation | $4.3M | $2.7M | $872.2K | $207.3K | $233.2K |
| Net Cash from Operating Activities | $-10.7M | $-10.3M | $-11.2M | $-7.2M | $-3.9M |
| Investing Activities | |||||
| Capital Expenditures | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — |
| Net Cash from Investing Activities | $-1.2M | $-25.0K | $-543.2K | $-525.0K | $-136.8K |
| Financing Activities | |||||
| Dividends Paid | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — |
| Net Cash from Financing Activities | $20.4M | $16.0M | $38.4M | $9.4M | $-340.6K |
| Net Change in Cash | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | — |